Bristol-Myers to acquire Amira

Bristol-Myers Squibb Co. (NYSE:BMY) will acquire Amira Pharmaceuticals Inc. (San Diego, Calif.) for $325 million in cash, plus up to $150 million in milestones. Bristol-Myers will gain Amira's AM152, an oral lysophosphatidic acid receptor 1 ( LPA1) antagonist that has completed Phase I testing to treat lung fibrosis of scleroderma and idiopathic pulmonary fibrosis (IPF). ...